Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05879744 · ClinicalTrials.gov registry record · Phase 1
A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)
A Phase 1 study of NHL and NHL, Relapsed, Adult, sponsored by Cullinan Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
- 6
- Study locations
NCT05879744 is a Phase 1 study of NHL and NHL, Relapsed, Adult that is active but no longer recruiting, run by Cullinan Therapeutics. The registered enrollment target is 90 participants, above the 80-participant average among 8 other NHL trials with a reported enrollment target (13% higher). The trial reports 6 study locations across 6 states.
The verdict
NCT05879744, a Phase 1 study of NHL and NHL, Relapsed, Adult, is active but no longer recruiting, sponsored by Cullinan Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
- 6
- Study locations
Study Summary
CLN-978-001 is a Phase 1, open-label, dose escalation and dose expansion study of CLN-978 in patients with Relapse/Refractory (R/R) B-cell Non-Hodgkin Lymphoma (B-NHL).
Conditions Studied
Interventions
- DRUG CLN-978
Study Locations (6)
Alabama
- University of Alabama at Birmingham - Birmingham
California
- City of Hope - Duarte
Georgia
- Winship Cancer Institute at Emory University - Atlanta
Massachusetts
- Massachusetts General Hospital - Boston
New Jersey
- Hackensack University Medical Center - Hackensack
Texas
- University of Texas Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2023-05-31 |
| Est. Completion | 2027-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05879744
The ClinicalTrials.gov registry entry for NCT05879744 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 80-participant average among 8 other NHL trials with a reported enrollment target (13% higher). The listed sponsor is Cullinan Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with NHL appearing as the primary indexed condition, and to 1 intervention - of which CLN-978 is the first listed.
NCT05879744 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Alabama, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT05879744 about?
NCT05879744 is a clinical study titled "A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)". CLN-978-001 is a Phase 1, open-label, dose escalation and dose expansion study of CLN-978 in patients with Relapse/Refractory (R/R) B-cell Non-Hodgkin Lymphoma (B-NHL).
What is the current status of trial NCT05879744?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2023-05-31. Estimated completion is 2027-04.
What conditions does trial NCT05879744 study?
This clinical trial studies the following conditions: NHL, NHL, Relapsed, Adult.
What interventions are being tested in trial NCT05879744?
The interventions under investigation include: CLN-978 (DRUG).
Who is sponsoring clinical trial NCT05879744?
This trial is sponsored by Cullinan Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05879744 being conducted?
This trial has 6 study locations across Alabama, California, Georgia, Massachusetts, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for NHL
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
RECRUITING · Phase 1
-
Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
COMPLETED · Phase 1
-
SBU-RESET: RElaxation, Stress Reduction and Epigenetics Trial in Cancer Survivors
RECRUITING · NA
-
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
RECRUITING · Phase 2
-
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.